Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Impedimed Limited ( (AU:IPD) ) is now available.
Impedimed Limited has announced the quotation of 6,281,809 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure and potentially increase its market presence. The release of these securities, previously issued under an employee incentive scheme, signifies a step towards greater liquidity and flexibility in the company’s financial operations, which could positively impact its stakeholders and market positioning.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, focusing on developing and providing non-invasive medical devices for the assessment of fluid status and body composition. The company’s primary products are used in healthcare settings to aid in the management of conditions such as lymphedema and heart failure.
Average Trading Volume: 2,305,831
Technical Sentiment Signal: Sell
Current Market Cap: A$79.16M
For an in-depth examination of IPD stock, go to TipRanks’ Overview page.